Activated EGFR promotes the survival of B-lineage acute leukemia in the absence of stromal cells

Cell Cycle

Volumn 4, Issue 3, 2005, Pages 483-487

  Spengeman, Justin D ^a   Green, Thomas D ^a   McCubrey, James A ^a   Bertrand, Fred E ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

B ALL; EGFR; Stromal cell; v ErbB

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ACUTE LEUKEMIA; ARTICLE; B CELL LEUKEMIA; BONE MARROW; CANCER CELL; CELL CULTURE; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DATA ANALYSIS; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; HUMAN CELL; STROMA CELL;

EID: 25144503757     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.4.3.1533     Document Type: Article

References (24)

1. Manabe A, Murti KG, Coustan-Smith E, Kumagai M, Behm FG, Raimondi SC, Campana D. Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood 1994; 83:758-66.
2. Shah N, Oseth L, Tran H, Hirsch B, LeBien TW. Clonal variation in the B-lineage acute lymphoblastic leukemia response to multiple cytokines and bone marrow stromal cells. Cancer Res 2001; 61:5268-74.
3. Vega F, Medeiros LJ, Lang W-H, Mansoor A, Bueso-Ramos C, Jone D. The stomal composition of malignant lymphoid aggregates in bone marrow: Variations in architecture and phenotype in different B-cell tumours. Br J Haemat 2002; 117:569-76.
4. Konopleva M, Konoplev S, Hu W, Zaritskey AY, Afanasiev BV, Andreeff M. Stromal cells prevent apoptosis of AML cell by upregulation of anti-apoptotic proteins. Leukemia 2003; 16:1713-24.
5. Kumagai M, Manabe A, Coustan-Smith E, Blakley RL, Beck WT, Santana VM, Behm FG, Raimondi SC, Campana D. Use of stroma-supported cultures of leukemic cells to access antileukemic drugs. II. Potent cytotoxicity of 2-chloro-deoxyadenosine in acute lymphoblastic leukemia. Leukemia 1994; 8:1116-23.
6. Fortney JE, Zhao W, Wenger SL, Gibson LF. Bone marrow stromal cells regulate caspase-3 activity in leukemic cells during chemotherapy. Leuk Res 2001; 25:901-7.
7. Mudry RE, Fortney JE, York T, Hall BM, Gibson LF. Stromal cells regulate survival of B-lineage leukemic cells during chemotherapy. Blood 2000; 96:1926-32.
8. Bertrand FE, Spengeman JD, Shelton JG, McCubrey JA. Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-lineage ALL in the presence of stromal cell support. Leukemia 2005; 19:98-102.
9. von Lindern M, Deiner EM, Dolznig H, Amelsvoort MP, Hayman MJ, Mullner EW, Beug H. Leukemic transformation of normal murine erythroid progenitors: V- and c-ErbB act through signaling pathways activated by the EpoR and c-kit in stress erythropoiesis. Oncogene 2001; 20:3651-64.
10. Holbro T, Hynes NE. ErbB receptors: Directing key signaling networks throughout life. Annu Rev Pharmacol Toxical 2004; 44:195-217.
11. Downward J, Yarden Y, Mayes E, Scrace G, Totty N, Stockwell P, Ullrich A, Schlessinger J, Waterfield MD. Close similarity of epidermal growth factor and v-erb-B oncogene protein sequences. Nature 1984; 307:521-7.
12. Kahn P, Frykberg L, Brady C, Stanley I, Beug H, Vennstrom B, Graf T. v-erbA cooperates with sarcoma oncogenes in leukemic cell transformation. Cell 1986; 45:349-56.
13. McCubrey JA, Shelton JG, Steelman LS, Franklin RA, Sreevalson T, McMahon M. Effects of a conditionally active v-ErbB and an EGFR inhibitor on transformation of NIH 3T3 cells and abrogation of cytokine dependency of hematopoietic cells. Oncogene 2004; 23:7810-20.
14. Shah N, Oseth L, LeBien TW. Development of a model for evaluating the interaction between human preB Acute lymphoblastic leukemic cells and the bone marrow stromal cell microenvironment. Blood 1998; 92:3817-28.
15. Bertrand FE, Vogtenhuber C, Shah N, LeBien TW. Pro-B cell to preB cell development in B-lineage acute lymphoblastic leukemia expressing the MLL/AF4 fusion protein. Blood 2001; 98:3398-405.
16. Harris RC, Chung E, Coffey RJ. EGF receptor ligands. Exp Cell Res 2003; 284:2-13.
17. Chang F, Steelman LS, McCubrey JA. Raf-induced cell cycle progression in human TF-1 hematopoietic cells. Cell Cycle 2002; 1:220-6.
18. Shelton JG, Blalock WL, White ER, Steelman LS, McCubrey JA. Ability of the activated PI3K/Akt oncoproteins to synergize with MEK1 and induce cell cycle progression and abrogate the cytokine-dependence of hematopoietic cells. Cell Cycle 2004; 3:503-12.
19. Shelton JG, Chang F, Lee JT, Franklin RA, Steelman LS, McCubrey JA. B-raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. Cell Cycle 2004; 3:189-96.
20. Mosesson Y, Yarden Y. Oncogenic growth factor receptors: Implications for signal transduction therapy. Sem Cancer Biol 2004; 14:262-70.
21. Jones FE, Golding JP, Gassmann M. ErbB4 signaling during brest and neural development: Novel genetic models revieal unique ErbB4 activiites. Cell Cycle 2003; 2:555-9.
22. Citri A, Kochupurakkal BS, Yarden Y. The Achilles heel of erbB-2/HER2: Regulation by the Hsp90 chaperone machine and potential for pharmacological intervention. Cell Cycle 2004; 3:51-60.
23. Seton-Rogers SE, Brugge JS. ErbB2 and TFG-β: A cooperative role in mammary tumor progression? Cell Cycle 2004; 3:597-600.
24. Birnbuam A, Ready N. Gefitnib therapy for nonsmall cell lung cancer. Curr Treat Optins Oncol 2005; 6:75-81.